| Similar Articles |
|---|
 |
The Motley Fool
September 29, 2004
Charly Travers |
Nabi Stamps Out Smoking A nicotine vaccine looks to help smokers kick the habit.   |
The Motley Fool
November 17, 2009
Brian Orelli |
This Partnership Is Smoking! Glaxo and Nabi team up for smokers who want to quit. Let's just hope they don't flame out in phase 3 trials. |
The Motley Fool
May 8, 2009
Brian Orelli |
Glaxo Goes Head-to-Head on HPV Glaxo's data may not be enough to help Cervarix knock Merck's Gardasil from the top papillomavirus vaccine spot. |
The Motley Fool
July 25, 2007
Brian Orelli |
Hopeful Flu Production Technology From Baxter While the clinical trial demonstrating strong immunogenicity for the new vaccine is certainly good news, the continued development of the production technology is probably the more important item for investors. |
Pharmaceutical Executive
June 1, 2005
Sibyl Shalo |
Chief of Staph Nabi, a small pharmaceutical company, has found a way to make money by making vaccines. Nabi now aims to become the first company to market a vaccine to attack the deadly staph bacterium. |
The Motley Fool
April 27, 2006
Stephen D. Simpson |
Glaxo's Story Still Worth Reading A good pipeline could keep GlaxoSmithKline's already-impressive shares rolling. |
The Motley Fool
December 23, 2003
David Nierengarten |
An Undervalued Biotech Nabi Biopharmaceuticals has revenues and a pipeline. Is it undervalued? |
The Motley Fool
May 27, 2005
Rich Duprey |
Glaxo's Flu Vaccine Booster The drug giant's return could give the U.S. flu vaccine market a shot in the arm. |
Chemistry World
October 9, 2013
Phillip Broadwith |
GSK to apply for malaria vaccine approval Preliminary results from the first ever Phase III clinical trial of a malaria vaccine show that it can reduce malaria infections in vaccinated children over 18 months. |
The Motley Fool
September 25, 2007
Brian Orelli |
Cold HIV Vaccine Gets Frozen Phase 2 clinical trials of Merck's HIV vaccine were frozen, leaving the door open for other drugmakers that have vaccines of their own in early trials. Investors, take note. |
The Motley Fool
September 7, 2005
Stephen D. Simpson |
Smashing Good Deal, Eh? Glaxo's purchase of Canadian ID Biomedical will seriously augment its vaccine capabilities. Investors, take note. |
The Motley Fool
June 26, 2008
Brian Lawler |
Gauging Glaxo's Vaccine Value Surprise! The FDA actually approves Glaxo's new combination children's vaccine without delay. |
The Motley Fool
July 5, 2006
Rich Duprey |
Flu Vaccine Deja Vu The country's largest vaccine maker, Sanofi Aventis, gets an FDA warning letter reminiscent of the 2004 debacle. |
Chemistry World
August 5, 2015
Emma Stoye |
Vaccine raises hopes of an end to Ebola A Phase III trial for a candidate Ebola vaccine has shown extremely encouraging results in Guinea, demonstrating complete protection for all those who were vaccinated. |
Pharmaceutical Executive
December 1, 2010
Walter Armstrong |
Nicotine Addiction: What Lights Up the Field The market for anti-smoking products exceeds $2 billion, but their superiority over cold-turkey quitting remains controversial. |
The Motley Fool
August 20, 2007
Brian Orelli |
Contracts That Are for the Birds Baxter and GlaxoSmithKline get bird flu vaccine contracts from the U.K. These contracts aren't reasons by themselves to run out and buy the companies' stock, but expanding income sources are almost always a good sign. |
Chemistry World
December 3, 2014
Maria Burke |
Ebola vaccine passes first safety hurdle The vaccine was developed collaboratively by scientists at the NIH's National Institute of Allergy and Infectious Diseases, and at Okairos, a biotechnology company acquired by GlaxoSmithKline. |
Chemistry World
January 29, 2015
Matthew Gunther |
Ebola vaccine shown to be safe in humans GlaxoSmithKline's experimental Ebola vaccine is capable of triggering an immune response in humans, according to a new study. |
Chemistry World
July 2007
Lisa Melton |
There's More to Quitting Than Nicotine As England joins the growing list of nations to ban smoking in enclosed public places, this article explores the medicinal arsenal that could help to kick the habit |
The Motley Fool
September 24, 2009
Brian Orelli |
Drugmakers' HIV Treatments Live On Companies that make HIV drugs could lose billions of dollars in revenue if an effective vaccine is developed. All drug-company investors need to keep an eye on up-and-coming drugs from competitors that could take market share. |
BusinessWeek
April 26, 2004
Kerry Capell |
Vaccinating The World's Poor GlaxoSmithKline Biologicals is betting it can combat Third World scourges -- and still make money. |
Pharmaceutical Executive
May 1, 2006
Pasternak et al. |
Vaccines: Market on the Rebound The vaccine business was safely inoculated against higher profits. But innovative therapies and looser government controls may spark an outbreak. Are pharmaceuticals ready for this opportunity? |
The Motley Fool
December 13, 2011
Frank Vinluan |
N.C. Novartis Site Is First Cell-Based Flu Vaccine Facility in the Country A Novartis' vaccine facility in North Carolina today became the first facility authorized by the FDA for emergency use during a pandemic. |
BusinessWeek
April 12, 2004
Catherine Arnst |
Killer Staph Is Hitting The Streets For the past 30 years, hospitals have been battling a mutant form called methicillin-resistant S. aureus (MRSA) that is resistant to penicillin-related antibiotics and is especially lethal. Now it's showing up in the general population. |
